- Details
- Diane Newman, an adult nurse practitioner and a continence nurse specialist in urology, provides an expert lecture on the growing future of nurse practitioners and physician assistants specifically in the field of urology. Both nurse practitioners and physician assistants were rated in the 100 best jobs by the US News and World Report in 2019. Diane K. Newman, DNP FAAN BCB-PMD , Urologic Nurse Pra...
|
- Details
- For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...
|
- Details
- Mike Craycraft, Testicular Cancer Survivor, Clinical Pharmacist and Founder of the Testicular Cancer Society joins Alicia Morgans in this special Testicular Cancer Awareness podcast. Mike shares what drove him to launch the Testicular Cancer Society, a nonprofit raising awareness for testicular cancer, promoting self-examination and helping survivors and caregivers navigate the diagnosis and treat...
|
- Details
- (Length of Interview: 13 min) Robert Voss, a 23-year prostate cancer survivor, shares why it is important to constantly educate yourself about the disease. Robert highlights the various ways to seek information from going to a teaching university hospital, searching the internet, to getting your significant other involved. 1. How did you go about making your treatment decision? 2. Did you feel tha...
|
- Details
- In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...
|
- Details
- (Length of Interview: 7 min) Malcolm McKay, a former school principal from Rochester, Minnesota, sits down and shares his prostate cancer story. Understanding his family history of prostate cancer led to Malcolm's participation in a clinical trial before ever being diagnosed. 1. How did you go about making your treatment decision? 2. Did you feel that you had an adequate understanding of all the p...
|
- Details
- Srikala (Kala) Sridhar joins Alicia Morgans to discuss highlights of the advanced prostate cancer consensus conference 2019 sessions. This conference focuses on areas that are controversial and do not have clear evidence to guide the process of prostate cancer care. They cover treatment of the primary in metastatic hormone-sensitive prostate cancer (mHSPC), the importance of understanding the biol...
|
- Details
- Diane Newman, an adult nurse practitioner, provides an expert lecture on draining issues in catheter bags. This is a problem that afflicts individuals with transurethral indwelling catheters and can be cause for concern for caregivers or patients, but Newman provides advice on how to remedy the issue. While some draining problems may be caused by obstruction of catheter eyes or bacteria and encrus...
|
- Details
- Recorded Date: April 1, 2020 Stephen Freedland speaks to Alicia Morgans about the changes COVID-19 has brought to his clinical practice and research in Los Angeles, California. Dr. Freedland reflects on his clinical practice, noting that the halting of elective procedures has canceled all Benign Prostatic Hyperplasia procedures, while prostate cancer patients are being assessed on a case-by-case b...
|
- Details
- Matthew Sydes joins Alicia Morgans to share his perspective on the data supporting a patient’s decision whether to use docetaxel or whether to use AR pathway inhibitors at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). The two discuss the direct and indirect methods of trial comparison and examine the data from trials that reported on docetaxel as well as the abiraterone clinical...
|
